Inventor Of R-salbutamol Dr Gunnar Aberg Joins Board of Perth-based Biotechnology Firm Stirling Products Limited

Inventor Of R-salbutamol Dr Gunnar Aberg Joins Board of Perth-based Biotechnology Firm Stirling Products Limited

The Inventor Of R-salbutamol Dr Gunnar Aberg Has Joined The Board of Perth-based Biotechnology Firm Stirling Products Limited.

Perth-based biotechnology company Stirling Products Limited (ASX: STI) has strengthened its Board of Directors with the appointment of the inventor of
its major animal growth promoter.

New Non-Executive Director, Dr Gunnar Aberg is one of the original developers and patent holders for R-salbutamol to which Stirling Products Limited acquired global rights for use in growth promotion.

“This is an exciting development for the company and adds to our expertise as a leader in the application of new technology to animal health and nutrition,” said Stirling Products Limited Managing Director, Dr Calvin London.

Dr Aberg is CEO of the Florida-based Bridge Pharma Inc, a company established to fulfil an increasing demand for developing therapeutic drugs
that conform to high international standards.

Bridge Pharma is also the largest shareholder in Stirling Products with an 11 per cent share in the company.

"Dr Aberg will bring added depth to our Board because of his immense experience in intellectual property development and commercialisation,
including an intimate knowledge of our lead product ST810" Dr London said.

ST810 fine-tunes the metabolism in animals to produce more lean muscle and less fat in a range of animal species.

About Stirling Products Limited

Stirling Products Limited is commercialising patented animal growth promoters that turn fat into protein and improve feed efficiencies in poultry, sheep, pigs,
cattle and fish.

These products will play a major role in reducing the global use of antibiotics and steroids for animal growth promotion.

About Dr Gunnar Aberg:

Prior to founding Bridge Pharma, Dr. Aberg held senior research management
positions in major European and US pharmaceutical companies. He has been
involved in research and development that has successfully guided numerous
pharmaceuticals onto the market including local anaesthetics,
antiarrhythmics, antiasthmatics, antihypertensives, and antihistamines. Dr
Aberg holds over 400 international and over 50 US patents.

ENDS

For All Media Enquiries Contact: Managing Director at http://www.stirlingproducts.net

Contact Information

Dr Calvin London

Managing Director

Thomas Murrell

Contact via E-mail